Form 4: Virios Therapeutics Director William Pridgen Acquires Stock Options

Director William Pridgen acquired stock options in Virios Therapeutics, Inc. on February 26, 2024.

Summary

• On February 26, 2024, William Pridgen, a director of Virios Therapeutics, Inc., acquired stock options.
• The stock options grant the right to buy 2,917 shares of common stock at an exercise price of $0.357 per share.
• The options vest 100% on February 26, 2025, and expire on February 26, 2034.
• Following the transaction, Pridgen directly owns 2,917 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director. While it can be seen as a positive sign of confidence, it's not a major event.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This filing provides transparency to the market regarding insider transactions.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's confidence in the company.

Key Dates

Keywords

Virios Therapeutics, Stock Options, Director, Beneficial Ownership, Form 4, VIRI, Pridgen